A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AURIEL-PsO
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 25 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2016 According to a Merck KGaA media release, first patient from phase III, AURIEL-PsO, study is being treated with adalimumab biosimilar.
    • 25 Feb 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top